Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-NK 002
- Development stage
- Preclinical
- Lead developer
- ThinkingBiomed
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-NK 002 is an induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor natural killer (CAR-NK) cell therapy being developed by ThinkingBiomed. The therapy utilizes iPSCs as a starting material to generate a standardized, "off-the-shelf" population of NK cells engineered with a chimeric antigen receptor to target tumor-associated antigens. Currently in the preclinical validation stage, CAR-NK 002 is intended for the treatment of solid tumors and hematological malignancies, including lung cancer, liver cancer, colorectal cancer, and B-cell lymphoma. The specific antigen target for this candidate has not been publicly disclosed.
02
Targets
ULBP6 (UL16-binding protein 6)
Beyond the preview
Go deeper on CAR-NK 002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-NK 002.